{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:29:35Z","timestamp":1763458175833,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"NIH NINDS T32 training","doi-asserted-by":"publisher","award":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"],"award-info":[{"award-number":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, HHS of the National Institutes of Health","doi-asserted-by":"publisher","award":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"],"award-info":[{"award-number":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIH NIAMS","doi-asserted-by":"publisher","award":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"],"award-info":[{"award-number":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association (MDA)","doi-asserted-by":"publisher","award":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"],"award-info":[{"award-number":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NIH National Institute of Neurological Disorders and Stroke (NINDS)","doi-asserted-by":"publisher","award":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"],"award-info":[{"award-number":["5T32NS095775","R01HD095897","R21AR074006","MDA418254","R01NS120060","R21NS114918"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is a progressive, X-linked childhood neuromuscular disorder that results from loss-of-function mutations in the DYSTROPHIN gene. DMD patients exhibit muscle necrosis, cardiomyopathy, respiratory failure, and loss of ambulation. One of the major driving forces of DMD disease pathology is chronic inflammation. The current DMD standard of care is corticosteroids; however, there are serious side effects with long-term use, thus identifying novel anti-inflammatory and anti-fibrotic treatments for DMD is of high priority. We investigated the next-generation SINE compound, KPT\u22128602 (eltanexor) as an oral therapeutic to alleviate dystrophic symptoms. We performed pre-clinical evaluation of the effects of KPT\u22128602 in DMD zebrafish (sapje) and mouse (D2-mdx) models. KPT\u22128602 improved dystrophic skeletal muscle pathologies, muscle architecture and integrity, and overall outcomes in both animal models. KPT\u22128602 treatment ameliorated DMD pathology in D2-mdx mice, with increased locomotor behavior and improved muscle histology. KPT\u22128602 altered the immunological profile of the dystrophic mice, and reduced circulating osteopontin serum levels. These findings demonstrate KPT\u22128602 as an effective therapeutic in DMD through by promotion of an anti-inflammatory environment and overall improvement of DMD pathological outcomes.<\/jats:p>","DOI":"10.3390\/biomedicines10102400","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T21:23:27Z","timestamp":1664313807000},"page":"2400","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Next-Generation SINE Compound KPT\u22128602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-5157","authenticated-orcid":false,"given":"Katherine G.","family":"English","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Neurology at Children\u2019s of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea L.","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neurology at Children\u2019s of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Samani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neurology at Children\u2019s of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald J. F.","family":"Coulis","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA 92697, USA"},{"name":"Institute for Immunology, University of California-Irvine, Irvine, CA 92967, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5212-2259","authenticated-orcid":false,"given":"S. Armando","family":"Villalta","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA 92697, USA"},{"name":"Institute for Immunology, University of California-Irvine, Irvine, CA 92967, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Walker","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Newton, MA 02459, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-1184","authenticated-orcid":false,"given":"Sharon","family":"Tamir","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics, Newton, MA 02459, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7406-5171","authenticated-orcid":false,"given":"Matthew S.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neurology at Children\u2019s of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA"},{"name":"UAB Center for Exercise Medicine (UCEM), Birmingham, AL 35205, USA"},{"name":"Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35233, USA"},{"name":"UAB Civitan International Research Center (CIRC), Birmingham, AL 35233, USA"},{"name":"UAB Center for Neurodegeneration and Experimental Therapeutics (CNET), Birmingham, AL 35294, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mus.23810","article-title":"Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy","volume":"48","author":"Mendell","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/352536a0","article-title":"The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy","volume":"352","author":"Stedman","year":"1991","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","article-title":"Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls","volume":"63","author":"Lundberg","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.nmd.2008.02.002","article-title":"Mdx respiratory impairment following fibrosis of the diaphragm","volume":"18","author":"Ishizaki","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"299rv294","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_7","first-page":"CD003725","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","volume":"2004","author":"Manzur","year":"2008","journal-title":"Cochrane Libr. Cochrane Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","article-title":"Biochemical characterization of patients with in-frame or out-of-frame dmd deletions pertinent to exon 44 or 45 skipping","volume":"71","author":"Anthony","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1083\/jcb.201212142","article-title":"Cellular and molecular mechanisms underlying muscular dystrophy","volume":"201","author":"Rahimov","year":"2013","journal-title":"J. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/01.wnl.0000173836.09176.c4","article-title":"Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy","volume":"65","author":"Chen","year":"2005","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/hmg\/ddu735","article-title":"Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy","volume":"24","author":"Giordano","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/acel.12350","article-title":"Increases of M2a macrophages and fibrosis in aging muscle are influenced by bone marrow aging and negatively regulated by muscle-derived nitric oxide","volume":"14","author":"Samengo","year":"2015","journal-title":"Aging Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1242\/jcs.083246","article-title":"The nuclear pore complex--structure and function at a glance","volume":"128","author":"Kabachinski","year":"2015","journal-title":"J. Cell Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","article-title":"Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia","volume":"34","author":"Alexander","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)\u2014A novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors","volume":"34","author":"Razak","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-014-2495-8","article-title":"KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma","volume":"74","author":"Zheng","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1074-5521(97)90257-X","article-title":"Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA","volume":"4","author":"Wolff","year":"1997","journal-title":"Chem. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1242\/jcs.113.3.451","article-title":"Developmentally regulated activity of CRM1\/XPO1 during early Xenopus embryogenesis","volume":"113","author":"Callanan","year":"2000","journal-title":"J. Cell Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1186\/s12885-015-1790-z","article-title":"Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds","volume":"15","author":"Crochiere","year":"2015","journal-title":"BMC Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.18632\/oncotarget.6495","article-title":"A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds","volume":"7","author":"Crochiere","year":"2015","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymthe.2019.08.016","article-title":"The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice","volume":"28","author":"Hightower","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-021-01032-2","article-title":"Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia","volume":"14","author":"Walker","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-16-1580","article-title":"The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia","volume":"23","author":"Vercruysse","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1158\/1078-0432.CCR-20-1315","article-title":"The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia","volume":"26","author":"Verbeke","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"viii716","DOI":"10.1093\/annonc\/mdy424.024","article-title":"Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)","volume":"29","author":"Hays","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_33","first-page":"e50925","article-title":"Analysis of Skeletal Muscle Defects in Larval Zebrafish by Birefringence and Touch-evoke Escape Response Assays","volume":"82","author":"Smith","year":"2013","journal-title":"J. Vis. Exp."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bbrc.2012.06.040","article-title":"Quantification of birefringence readily measures the level of muscle damage in zebrafish","volume":"423","author":"Berger","year":"2012","journal-title":"Biochem. Biophys Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pbb.2014.08.010","article-title":"Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice","volume":"126","author":"Gonzales","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_37","unstructured":"Bernardini, C. (2018). Characterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry. Duchenne Muscular Dystrophy: Methods and Protocols, Springer."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/hmg\/ddv460","article-title":"Effect of genetic background on the dystrophic phenotype in mdx mice","volume":"25","author":"Coley","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1096\/fj.201802488R","article-title":"Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy","volume":"33","author":"Putker","year":"2019","journal-title":"FASEB J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.1038\/s41598-020-70987-y","article-title":"The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy","volume":"10","author":"Hammers","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1152\/japplphysiol.00162.2019","article-title":"Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice","volume":"127","author":"Spaulding","year":"2019","journal-title":"J. Appl. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hammers, D.W., Sleeper, M.M., Forbes, S.C., Coker, C.C., Jirousek, M.R., Zimmer, M., Walter, G.A., and Sweeney, H.L. (2016). Disease-modifying effects of orally bioavailable NF-\u03baB inhibitors in dystrophin-deficient muscle. JCI Insight, 1.","DOI":"10.1172\/jci.insight.90341"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/mus.25517","article-title":"Genetic ablation of P65 subunit of NF-\u03baB in mdx mice to improve muscle physiological function","volume":"56","author":"Yin","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1093\/hmg\/ddz181","article-title":"Spp1 (osteopontin) promotes TGF\u03b2 processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases","volume":"28","author":"Kramerova","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtn.2018.02.002","article-title":"Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse","volume":"11","author":"Wang","year":"2018","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Li, J., Fredericks, M., Cannell, M., Wang, K., Sako, D., Maguire, M.C., Grenha, R., Liharska, K., Krishnan, L., and Bloom, T. (2021). ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J. Clin. Investig., 131.","DOI":"10.1172\/JCI138634"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/hmg\/ddn376","article-title":"Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy","volume":"18","author":"Villalta","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI30556","article-title":"Interplay of IKK\/NF-\u03baB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy","volume":"117","author":"Acharyya","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1010966","DOI":"10.1080\/21675511.2015.1010966","article-title":"The immune system in Duchenne muscular dystrophy: Friend or foe","volume":"3","author":"Villalta","year":"2015","journal-title":"Rare Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.4049\/jimmunol.1101342","article-title":"Osteopontin-Stimulated Expression of Matrix Metalloproteinase-9 Causes Cardiomyopathy in the mdx Model of Duchenne Muscular Dystrophy","volume":"187","author":"Dahiya","year":"2011","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1172\/JCI37662","article-title":"Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-\u03b2","volume":"119","author":"Vetrone","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ajpath.2016.01.002","article-title":"Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy","volume":"186","author":"Kuraoka","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.0b013e318207afeb","article-title":"SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy","volume":"76","author":"Pegoraro","year":"2011","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/jnnp-2014-308409","article-title":"Validation of genetic modifiers for Duchenne muscular dystrophy: A multicentre study assessing SPP1 and LTBP4 variants","volume":"86","author":"Hiller","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Capote, J., Kramerova, I., Martinez, L., Vetrone, S., Barton, E.R., Sweeney, H.L., Miceli, M.C., and Spencer, M.J. (2016). Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype. J. Cell Biol.","DOI":"10.1083\/jcb.201510086"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1158\/0008-5472.CAN-17-1323","article-title":"Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors","volume":"77","author":"Conforti","year":"2017","journal-title":"Cancer Res."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:39:30Z","timestamp":1760143170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biomedicines10102400"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10102400","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}